Access Pharmaceuticals has signed a collaborative agreement with bioRASI to facilitate clinical development for its Cobalamin-based oral insulin and other products.
The partners will focus on conducting a first-in-man study for oral insulin and confirming the oral bioavailability.
bioRASI will utilise its translational clinical development process, which can generate human proof-of-principle data quickly and cost effectively.
bioRasi will conduct the preclinical and clinical studies in Russia and follow guidelines to support regulatory submissions in Europe, Japan and the US.
Access will also receive assistance from bioRASI in finding partners in Russia, CIS and other eastern European countries.